- Home
- EPIX vs HLVX Comparison
EPIX vs HLVX Comparison
Compare EPIX & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EPIX
- HLVX
- Stock Information
- Founded
- EPIX 2009
- HLVX 2020
- Country
- EPIX Canada
- HLVX United States
- Employees
- EPIX N/A
- HLVX N/A
- Industry
- EPIX Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- EPIX Health Care
- HLVX Health Care
- Exchange
- EPIX Nasdaq
- HLVX Nasdaq
- Market Cap
- EPIX 73.5M
- HLVX 87.6M
- IPO Year
- EPIX N/A
- HLVX 2022
- Fundamental
- Price
- EPIX $1.62
- HLVX $1.91
- Analyst Decision
- EPIX Hold
- HLVX Hold
- Analyst Count
- EPIX 3
- HLVX 5
- Target Price
- EPIX $2.00
- HLVX $2.33
- AVG Volume (30 Days)
- EPIX 286.3K
- HLVX 245.3K
- Earning Date
- EPIX 02-11-2025
- HLVX 11-07-2024
- Dividend Yield
- EPIX N/A
- HLVX N/A
- EPS Growth
- EPIX N/A
- HLVX N/A
- EPS
- EPIX N/A
- HLVX N/A
- Revenue
- EPIX N/A
- HLVX N/A
- Revenue This Year
- EPIX N/A
- HLVX N/A
- Revenue Next Year
- EPIX N/A
- HLVX N/A
- P/E Ratio
- EPIX N/A
- HLVX N/A
- Revenue Growth
- EPIX N/A
- HLVX N/A
- 52 Week Low
- EPIX $1.40
- HLVX $1.55
- 52 Week High
- EPIX $11.67
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- EPIX 25.75
- HLVX 47.67
- Support Level
- EPIX $1.63
- HLVX $1.88
- Resistance Level
- EPIX $1.74
- HLVX $2.13
- Average True Range (ATR)
- EPIX 0.06
- HLVX 0.07
- MACD
- EPIX 0.10
- HLVX -0.01
- Stochastic Oscillator
- EPIX 12.82
- HLVX 15.56
About EPIX ESSA Pharma Inc.
ESSA Pharma Inc is a pharmaceutical company. The company is focused on the development of small molecule drugs for the treatment of castration-resistant prostate cancer. The company is developing drugs that selectively block the amino-terminal domain of the androgen receptor, potentially overcoming the known AR-dependent resistance mechanisms of CRPC and providing CRPC patients with the potential for increased progression-free and overall survival.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.